Laster KV - Search Results

1

Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR.

Zhang Y, Shi X, Xie X, Laster KV, Pang M, Liu K, Hwang J, Kim DJ. Zhang Y, et al. Among authors: laster kv. Phytother Res. 2021 Nov;35(11):6377-6388. doi: 10.1002/ptr.7289. Epub 2021 Sep 20. Phytother Res. 2021. PMID: 34545650

2

2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo.

Zu X, Ma X, Xie X, Lu B, Laster K, Liu K, Dong Z, Kim DJ. Zu X, et al. J Exp Clin Cancer Res. 2020 Jun 9;39(1):107. doi: 10.1186/s13046-020-01608-9. J Exp Clin Cancer Res. 2020. PMID: 32517736 Free PMC article.

3

Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer.

Jin G, Yan M, Liu K, Yao K, Chen H, Zhang C, Yi Y, Reddy K, Gorja DR, Laster KV, Guo Z, Dong Z. Jin G, et al. Among authors: laster kv. Oncogene. 2020 Oct;39(43):6733-6746. doi: 10.1038/s41388-020-01467-w. Epub 2020 Sep 22. Oncogene. 2020. PMID: 32963350

4

Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.

Xie X, Wang X, Shi X, Zhang Y, Laster KV, Liu K, Dong Z, Kim DJ. Xie X, et al. Among authors: laster kv. J Cell Mol Med. 2021 Mar;25(5):2645-2654. doi: 10.1111/jcmm.16289. Epub 2021 Feb 1. J Cell Mol Med. 2021. PMID: 33523587 Free PMC article.

5

2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells.

Xie X, Zu X, Laster K, Dong Z, Kim DJ. Xie X, et al. J Pharmacol Sci. 2021 Mar;145(3):279-288. doi: 10.1016/j.jphs.2021.01.003. Epub 2021 Jan 7. J Pharmacol Sci. 2021. PMID: 33602509 Free article.

6

3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo.

Fu X, Zhao R, Yoon G, Shim JH, Choi BY, Yin F, Xu B, Laster KV, Liu K, Dong Z, Lee MH. Fu X, et al. Among authors: laster kv. Front Cell Dev Biol. 2021 Mar 25;9:638174. doi: 10.3389/fcell.2021.638174. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33842463 Free PMC article.

7

Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts.

Ma F, Laster K, Nie W, Liu F, Kim DJ, Lee MH, Bai R, Yang R, Liu K, Dong Z. Ma F, et al. J Cancer. 2021 May 10;12(13):3930-3944. doi: 10.7150/jca.52286. eCollection 2021. J Cancer. 2021. PMID: 34093800 Free PMC article.

8

Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo.

Shi X, Zhang Y, Xie X, Pang M, Laster K, Li J, Ma X, Liu K, Dong Z, Kim DJ. Shi X, et al. Front Oncol. 2021 Jun 10;11:648809. doi: 10.3389/fonc.2021.648809. eCollection 2021. Front Oncol. 2021. PMID: 34178634 Free PMC article.

9

Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma.

Liu F, Wu Q, Han W, Laster K, Hu Y, Ma F, Chen H, Tian X, Qiao Y, Liu H, Kim DJ, Dong Z, Liu K. Liu F, et al. Clin Transl Med. 2021 Oct;11(10):e548. doi: 10.1002/ctm2.548. Clin Transl Med. 2021. PMID: 34709754 Free PMC article.

10

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.

Wu Q, Liu F, Ge M, Laster KV, Wei L, Du R, Jiang M, Zhang J, Zhi Y, Jin G, Zhao S, Kim DJ, Dong Z, Liu K. Wu Q, et al. Among authors: laster kv. Oncogene. 2022 Jan;41(3):347-360. doi: 10.1038/s41388-021-02099-4. Epub 2021 Nov 8. Oncogene. 2022. PMID: 34750516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters